Related Experiment Videos
ABL1 amplification in T-cell acute lymphoblastic leukemia.
Paolo Bernasconi1, Silvia Calatroni, Ilaria Giardini
1Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi No. 5, 27100 Pavia, Italy. p.bernasconi@smatteo.pv.it
Cancer Genetics and Cytogenetics
|October 11, 2005
Summary
ABL1 amplification, a novel genetic defect in T-cell acute lymphoblastic leukemia (T-ALL), was identified in 6.6% of adult patients. Fluorescence in situ hybridization (FISH) promptly detects this, enabling targeted imatinib therapy.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous malignancy.
- Genetic abnormalities play a crucial role in T-ALL pathogenesis and treatment response.
- ABL1 amplification, linked to NUP214/ABL1 translocation, is an emerging genetic defect in T-ALL.
Observation:
- This study investigated the incidence and clinical features of ABL1 amplification in 30 adult T-ALL patients.
- Multiple copies of the ABL1 gene were detected in two patients (6.6%) using fluorescence in situ hybridization (FISH).
- Elevated ABL1 gene expression was confirmed via quantitative reverse-transcriptase polymerase chain reaction (RT-PCR).
Findings:
- FISH is the primary method for rapid identification of T-ALL with ABL1 amplification.
- Patients with ABL1 amplification showed significantly higher ABL1 gene expression compared to normal controls.
- Gene expression normalized upon achieving complete remission, suggesting its utility in monitoring disease status.
Implications:
- Prompt identification of ABL1 amplification via FISH is critical for initiating imatinib therapy.
- This subset of T-ALL is sensitive to imatinib but may develop resistance through additional mutations.
- Quantitative RT-PCR for ABL1 serves as a valuable tool for monitoring minimal residual disease in T-ALL.